RHHBY Roche Holding AG ADR

FDA Catalyst Company
41.11
+0.37  (+1%)
Previous Close 40.74
Open 40.93
52 Week Low 39.32
52 Week High 53.86
Market Cap $280,949,325,779
Shares 6,834,087,224
Float 6,834,087,224
Enterprise Value $300,045,355,953
Volume 8,161,389
Av. Daily Volume 2,500,988
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Cowen & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/22/2021
Deutsche Bank Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/08/2021

Latest News

    • Almost half of the world's population has no or limited access to diagnostics
    • This situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIV
    • New partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treated

    Basel, 12 May 2022 - Roche ((SIX: RO, ROG, OTCQX:RHHBY), through its Global Access Program, and The Global Fund to Fight AIDS, Tuberculosis and Malaria are joining forces to build and strengthen diagnostic capacity and pandemic…

    View Full Article
    • The SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq did not meet its co-primary endpoint of progression-free survival
    • The other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysis
    • The tiragolumab development programme continues as planned in non-small cell lung cancer and other cancer types

    Basel, 11 May 2022 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC). The study did not…

    View Full Article
    • The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
    • Prophylactic treatment aims to prevent bleeds and allow people with haemophilia to achieve quality of life comparable to non-haemophilic individuals. Access to this is particularly restricted in developing countries, with the limited healthcare resources reserved for emergency situations and acute bleeds
    • More than 940 people across 30 countries have already benefited from Roche's donations since the start of the partnership in February 2019

    Basel, 10 May 2022 – Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that it has extended its commitment…

    View Full Article
    • 91% of infants treated with Evrysdi in the FIREFISH study were still alive at three years
    • Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 and 30 seconds
    • Evrysdi has proven efficacy in infants and adults, with over 5,000 patients treated to date

    Basel, 29 April 2022 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi® (risdiplam) in infants with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed an estimated 91% of infants (n=58) treated with Evrysdi were alive after three…

    View Full Article
    • In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive care
    • More than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7
    • If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe

    Basel, 22 April 2022 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as an adjuvant…

    View Full Article
View All Roche Holding AG ADR News